uniQure N.V (F:UQ1) — Market Cap & Net Worth
Market Cap & Net Worth: uniQure N.V (UQ1)
uniQure N.V (F:UQ1) has a market capitalization of $1.46 Billion (€1.25 Billion) as of September 21, 2026. Listed on the F stock exchange, this Germany-based company holds position #7368 globally and #1019 in its home market, demonstrating a -1.29% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying uniQure N.V's stock price €38.25 by its total outstanding shares 63067485 (63.07 Million). Also see UQ1 asset base for a full breakdown of the balance sheet.
uniQure N.V Market Cap History: 2015 to 2026
uniQure N.V's market capitalization history from 2015 to 2026. Data shows growth from $1.03 Billion to $2.82 Billion (7.38% CAGR). Also see cash efficiency ratio of uniQure N.V for how efficiently the company converts equity into cash flow.
uniQure N.V Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how uniQure N.V's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check latest uniQure N.V stock price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
94.54x
uniQure N.V's market cap is 94.54 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $393.07 Million | $25.10 Million | -$73.37 Million | 15.66x | N/A |
| 2017 | $1.18 Billion | $13.11 Million | -$79.26 Million | 89.92x | N/A |
| 2018 | $1.64 Billion | $11.28 Million | -$83.30 Million | 145.06x | N/A |
| 2019 | $4.70 Billion | $7.28 Million | -$124.20 Million | 646.08x | N/A |
| 2020 | $2.16 Billion | $37.51 Million | -$125.02 Million | 57.71x | N/A |
| 2021 | $1.32 Billion | $524.00 Million | $329.59 Million | 2.53x | 4.02x |
| 2022 | $1.54 Billion | $106.48 Million | -$126.79 Million | 14.50x | N/A |
| 2023 | $440.92 Million | $15.84 Million | -$308.48 Million | 27.83x | N/A |
| 2024 | $1.24 Billion | $27.12 Million | -$239.56 Million | 45.57x | N/A |
| 2025 | $1.52 Billion | $16.10 Million | -$198.97 Million | 94.54x | N/A |
Competitor Companies of UQ1 by Market Capitalization
Companies near uniQure N.V in the global market cap rankings as of September 21, 2026. Review uniQure N.V tangible book value ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to uniQure N.V by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #189 globally with a market cap of $128.84 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #340 globally with a market cap of $79.38 Billion USD.
- CSL Ltd (AU:CSL): Ranked #459 globally with a market cap of $60.28 Billion USD ( AU$85.19 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #189 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $128.84 Billion | $508.34 |
| #340 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.38 Billion | $784.85 |
| #459 | CSL Ltd | AU:CSL | $60.28 Billion | AU$175.59 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $154.04 |
uniQure N.V Historical Marketcap From 2015 to 2026
Between 2015 and today, uniQure N.V's market cap moved from $1.03 Billion to $ 2.82 Billion, with a yearly change of 7.38%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €2.82 Billion | +85.32% |
| 2025 | €1.52 Billion | +23.15% |
| 2024 | €1.24 Billion | +180.27% |
| 2023 | €440.92 Million | -71.44% |
| 2022 | €1.54 Billion | +16.66% |
| 2021 | €1.32 Billion | -38.86% |
| 2020 | €2.16 Billion | -53.98% |
| 2019 | €4.70 Billion | +187.39% |
| 2018 | €1.64 Billion | +38.89% |
| 2017 | €1.18 Billion | +199.83% |
| 2016 | €393.07 Million | -61.88% |
| 2015 | €1.03 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 21st, 2026 the market cap of uniQure N.V was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.46 Billion USD |
| MoneyControl | $1.46 Billion USD |
| MarketWatch | $1.46 Billion USD |
| marketcap.company | $1.46 Billion USD |
| Reuters | $1.46 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About uniQure N.V
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. Th… Read more